- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 833899 [Title] => Novartis cancer drug gets Phl FDA approval [Summary] =>The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 779855 [Title] => Novartis, NKTI tie up to help GEP NET patients [Summary] =>Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 700713 [Title] => Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't [Summary] =>Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
[DatePublished] => 2011-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
DR. JOSEPH TOVERA
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 833899 [Title] => Novartis cancer drug gets Phl FDA approval [Summary] =>The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
[DatePublished] => 2012-08-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 779855 [Title] => Novartis, NKTI tie up to help GEP NET patients [Summary] =>Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.
[DatePublished] => 2012-02-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 700713 [Title] => Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't [Summary] =>Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.
[DatePublished] => 2011-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2/LVM - 14 16
SUERTRES - 8 3 2
6D Lotto - 9 0 3 0
6/45 Lotto - 41 44 23 3 17 5
P94,470,811.00
6/58 Ultra Lotto - 46 19 11 40 41 16
P228,127,654.00
- 12:00 am